{"nct_id":"NCT03439046","title":"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant","status":"COMPLETED","status_verified_date":"2024-07","start_date":"2018-02-02","start_date_type":"ACTUAL","primary_completion_date":"2023-12-11","primary_completion_date_type":"ACTUAL","completion_date":"2023-12-11","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["NVS"]}